Pfizer’s future lead obesity candidate from Metsera needs to match Zepboundnews2025-09-23T10:51:20+00:00September 23rd, 2025|Endpoints News|
FDA rejects Rexulti-Zoloft combo for PTSDnews2025-09-22T19:07:14+00:00September 22nd, 2025|Endpoints News|
Post-Hoc: Pharma threatens the UK to send a message to Europenews2025-09-22T16:24:01+00:00September 22nd, 2025|Endpoints News|
Ionis says RNA drug for rare brain disorder succeeded pivotal trial, plans to ask for FDA approvalnews2025-09-22T15:23:36+00:00September 22nd, 2025|Endpoints News|
FDA pushes back decision on Sanofi’s BTK inhibitor; Roche makes a deal with Starpharmanews2025-09-22T15:15:10+00:00September 22nd, 2025|Endpoints News|
Bristol Myers to launch schizophrenia drug in the UK at the same price as in the USnews2025-09-22T15:11:00+00:00September 22nd, 2025|Endpoints News|
FDA approves Stealth’s rare disease drug after past rejection, delaynews2025-09-22T15:05:16+00:00September 22nd, 2025|Endpoints News|
Avenzo collects another $60M for two small molecules and two ADCs licensed from Chinanews2025-09-22T13:00:50+00:00September 22nd, 2025|Endpoints News|
MBX Biosciences shares Phase 2 hypoparathyroidism data as it seeks to compete with Ascendis, AstraZenecanews2025-09-22T11:00:01+00:00September 22nd, 2025|Endpoints News|
Pfizer goes full speed ahead on obesity with $4.9B acquisition of Metseranews2025-09-22T10:49:36+00:00September 22nd, 2025|Endpoints News|
